MEDISPA.PRO
Ministry of Health code: A17.23.004.001 Axis M7 · Neuroplasticity and stress adaptation CEBM: Level A (Neuromodulation and device-based neurology)

Rhythmic transcranial magnetic stimulation (rTMS)

Repetitive Transcranial Magnetic Stimulation (rTMS)

Industry clinical and economic procedure passport. Full biological mechanism (MoA), patient preparation protocol, first-choice equipment fleet, integration into the resort's master treatment rooms and market price benchmarks.

To the procedure catalogue Equipment fleet Integration treatment rooms Rates and economics
Session duration
30 min
Turnover: ~45 min
Recommended course
10 sessions
daily (10–15 sessions)
Throughput capacity
11 pts
per 8-hour shift
Median rate
5 000 ₽
5 000 ₽ – 5 000 ₽
Course cost
50 000 ₽
at market median
Publication volume
Level A
10 publ. in PubMed

Clinical profile

Non-invasive stimulation of the cerebral cortex with a series of magnetic pulses. European guidelines rate depression, neuropathic pain and upper-limb motor recovery after stroke as level A; there are fewer data for other conditions, and in PTSD Cochrane has not yet found a difference from sham.

Every statement links to a publication in the list below. This is a snapshot of published research, not a final assessment of the method: international practice and integrated protocols often run ahead of official publications. Draft based on published research; requires review by a physician. Revision: 2026-10-17.

Mechanism of action

  • Stimulation of the left dorsolateral prefrontal cortex acts on specific symptom clusters in various neuropsychiatric disorders. [3]
  • High-frequency stimulation of the motor cortex contralateral to the pain reduces neuropathic pain; low-frequency stimulation of the healthy hemisphere helps upper-limb recovery after stroke. [1]

Where studies show an effect

  • Depression, including treatment-resistant: high-frequency stimulation of the left DLPFC, level of evidence A. [1, 2]
  • Neuropathic pain: high-frequency motor cortex stimulation, level A. [1]
  • Motor recovery after stroke, level A–B; a meta-analysis of RCTs confirms benefit, especially in the first six months. [1, 4]
  • Fibromyalgia: improved quality of life one month after starting the course. [6, 1]
  • Chronic tinnitus: meta-analyses show symptom reduction based on a limited number of studies. [7, 8]
  • Post-stroke cognitive impairment: combined with cognitive training, improvement in global cognitive function and daily activities. [5]

Open questions and study limitations

  • Post-traumatic stress disorder: probably little or no difference from sham immediately after the course (Cochrane, moderate certainty). [10]
  • For tinnitus, Cochrane found only very limited support for low-frequency stimulation. [9]
  • A significant difference from sham does not always mean a clinically meaningful effect. [1]
  • For memory after stroke, combination with cognitive training gave no advantage. [5]

Safety

  • Daily stimulation of the left prefrontal cortex has a substantial safety evidence base in depression. [2]
  • In tinnitus, stimulation is safe in the short term; data on long-term safety are insufficient. [9, 7]

Protocol in studies

  • Depression: daily stimulation of the left prefrontal cortex in the acute phase; options include high-frequency, theta-burst and bilateral. [2, 1]
Contraindications. Contraindications (including metal implants in the head and seizure susceptibility) are determined by the physician according to the stimulator's instructions; they are not given in study abstracts.

Equipment fleet and fit-out

Certified first-choice medical equipment and compatible device systems

Equipment registry
Base configuration (Hero Device)
Magstim Super Rapid Plus magnetic stimulator / Neuro-MS/D

Device platform with proven validation of the biological response. Includes built-in biofeedback sensor systems, patient protection protocols and precision dosing of exposure.

Certification: Russian Ministry of Health registration certificate / CE Medical Device Directive Class IIa/IIb.
Compatible platforms in the MEDISPA.PRO registry
Neuro-MS/D magnetic stimulator (Transcranial magnetic stimulation, TMS)
Medical device, Roszdravnadzor registration certificate / CE
In the registry →

Architectural integration and treatment rooms

Resort rooms housing the treatment station (with SanPiN norms and MEP loads)

All treatment rooms →
1.3.2 18.0 m² · Class B

Deep electromagnetic stimulation room

General therapeutic interventions and high-tech therapy · Equipment: 6 743 400 ₽

Treatment room passport →
1.1.1 20.0 m² · Class B/V

Neurologist's consulting room

Physicians' consulting and examination rooms · Equipment: 3 183 500 ₽

Treatment room passport →

Unit economics and resort price benchmarks

Market analysis based on a sample of premium sanatoriums, wellness hotels and preventive medicine clinics

Market price corridor
25th percentile (P25) 5 000 ₽
Market median 5 000 ₽
75th percentile (P75) 5 000 ₽

Median of prices in industry facilities' price lists, 2026

Basis of the price benchmark

Prices for this procedure appear in the price lists of 1 industry facilities; the median and interquartile range across facilities are shown (each facility counts once).

Evidence base

European guidelines based on replicated RCTs give level A for depression, neuropathic pain and upper-limb recovery after stroke; evidence for tinnitus and PTSD is weak or negative.

Publication level A · Plenty of data
  1. 1.
    Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018).
    Clin Neurophysiol, 2020 · Expert clinical guidelines (Europe) · PMID 31901449
    Level A: depression, neuropathic pain, upper-limb recovery after stroke; level B: fibromyalgia, Parkinson's disease, spasticity in MS, PTSD, aphasia; data for other conditions are still insufficient.
  2. 2.
    The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder.
    Brain Stimul, 2016 · Clinical TMS Society consensus · PMID 27090022
    Daily stimulation of the left prefrontal cortex is effective and safe in the acute phase of depression with drug resistance or intolerance.
  3. 3.
    Effects of repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex on symptom domains in neuropsychiatric disorders: a systematic review and cross-diagnostic meta-analysis.
    Lancet Psychiatry, 2023 · Systematic review and meta-analysis · PMID 36898403
    Left DLPFC stimulation is effective for specific symptom domains in various neuropsychiatric disorders.
  4. 4.
    Repetitive Transcranial Magnetic Stimulation for Motor Recovery After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Low Risk of Bias.
    Neuromodulation, 2025 · Systematic review and meta-analysis of RCTs · PMID 39320286
    rTMS promotes motor recovery after stroke, especially in the first six months and after severe stroke.
  5. 5.
    Repetitive transcranial magnetic stimulation combined with cognitive training for cognitive function and activities of daily living in patients with post-stroke cognitive impairment: A systematic review and meta-analysis.
    Ageing Res Rev, 2023 · Systematic review and meta-analysis · PMID 37004840
    rTMS with cognitive training improves cognitive function and daily activities after stroke, but not memory; the certainty of evidence is low.
  6. 6.
    Repetitive Transcranial Magnetic Stimulation for Fibromyalgia: Systematic Review and Meta-Analysis.
    Pain Pract, 2016 · Systematic review and meta-analysis · PMID 25581213
    Fibromyalgia: quality of life better than with sham one month after starting treatment.
  7. 7.
    Repetitive transcranial magnetic stimulation on chronic tinnitus: a systematic review and meta-analysis.
    BMC Psychiatry, 2020 · Systematic review and meta-analysis · PMID 33228598
    rTMS is effective in chronic tinnitus; safety and effect require large studies.
  8. 8.
    An updated meta-analysis: repetitive transcranial magnetic stimulation for treating tinnitus.
    J Int Med Res, 2021 · Meta-analysis · PMID 33729855
    Reduced tinnitus symptoms, with a weak immediate effect on some scales.
  9. 9.
    Repetitive transcranial magnetic stimulation for tinnitus.
    Cochrane Database Syst Rev, 2011 · Cochrane systematic review · PMID 21975776
    Very limited support for low-frequency rTMS in tinnitus; safe in the short term.
  10. 10.
    Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults.
    Cochrane Database Syst Rev, 2024 · Cochrane systematic review · PMID 39092744
    PTSD: active rTMS is probably little different from sham immediately after treatment.

Publications were found in PubMed; titles and journals are given verbatim, conclusions are a brief summary of the abstracts under the conditions of the specific studies. The level shows the volume of published data, not the value of the method: A — Plenty of data: consistent systematic reviews and meta-analyses of RCTs; B — Some data: reviews or several RCTs, results are heterogeneous; C — Little data: single RCTs or controlled studies; D — Scarce data: mainly reviews, observational and experimental studies. The passport is updated as new work is published and with regard to international practice.